Bharat Biotech s Covaxin shows 77.8% efficacy in Phase 3 trial
Bharat Biotech on Saturday announced the efficacy analysis data from Phase 3 clinical trials of its Covid vaccine Covaxin. The vaccine has been found to be 77.8 per cent effective.
advertisement
UPDATED: July 3, 2021 08:49 IST
Bharat Biotech on Saturday announced that Covaxin has been found to be 77.8 per cent effective against symptomatic Covid-19. (Photo: File)
Bharat Biotech concluded the final analysis of its Covid-19 vaccine Covaxin and announced the safety and efficacy analysis data from Phase 3 clinical trials on Saturday. As per this, Covaxin has been found to be 77.8 per cent effective against symptomatic Covid-19.
Bharat Biotech says no wrongdoing amid Brazil Covaxin controversy; all you need to know msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
As coronavirus situation turns grim across India, a shop in Uttar Pradesh, which earlier sold items for wedding ceremonies, is now forced to sell items needed for last rites.